Radiation Therapy Modulates DNA Repair Efficiency in Peripheral Blood Mononuclear Cells of Patients With Non-Small Cell Lung Cancer.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 22 04 2018
revised: 18 09 2018
accepted: 01 10 2018
pubmed: 13 10 2018
medline: 6 8 2019
entrez: 13 10 2018
Statut: ppublish

Résumé

There is growing interest in developing individually tailored cancer radiation therapy (RT), wherein patients with high intrinsic radiosensitivity are identified before commencing treatment, to minimize severe adverse reactions. In a previous retrospective study of severely radiosensitive RT patients, we established a functional assay with a high predictive capability. The assay involves ex vivo irradiation of peripheral blood mononuclear cells and analysis of DNA repair using the γ-H2AX assay. It is unknown whether RS is a fixed phenomenon or is modulated under different conditions. We now report the impact of RT on the apparent radiosensitivity, as reflected by the assay. Peripheral blood mononuclear cells of 11 patients with non-small cell lung cancer were collected before, during, and after RT. Quantitative parameters derived from the nonlinear regression analysis of γ-H2AX foci were applied to examine the cellular radiation response. Although the repair rate and foci yield remained constant during and after RT, the "unrepairable" component of γ-H2AX foci decreased over the course of treatment in 7 patients, signifying a generally enhanced DNA repair capacity. Interestingly, enhanced repair capacity tended to be associated with a poorer response to RT. Although generalization of these results into normal and tumor tissues warrants further investigation, the findings of this study have important implications in future strategies for identifying radiosensitive individuals before exposure to RT. We can anticipate that the threshold values that will discriminate radiosensitive patients in a future prospective trial will differ from those established in the retrospective study.

Identifiants

pubmed: 30312716
pii: S0360-3016(18)33833-1
doi: 10.1016/j.ijrobp.2018.10.001
pii:
doi:

Substances chimiques

H2AX protein, human 0
Histones 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

521-531

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Xiaoyu Yin (X)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.

Joel Mason (J)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Pavel N Lobachevsky (PN)

Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Laura Munforte (L)

Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Lisa Selbie (L)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

David L Ball (DL)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

Roger F Martin (RF)

Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; School of Chemistry, The University of Melbourne, Melbourne, Victoria, Australia.

Trevor Leong (T)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

Shankar Siva (S)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; School of Chemistry, The University of Melbourne, Melbourne, Victoria, Australia.

Olga A Martin (OA)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. Electronic address: olga.martin@petermac.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH